News & Updates

From flare-ups to freedom: Real-world applications of upadacitinib in difficult-to-treat atopic dermatitis

In this article, Dr Marco Ho discusses the applications of upadacitinib in managing severe, difficult-to-treat atopic dermatitis. Dr Ho emphasises the existing unmet need in Hong Kong, particularly in the head and neck region, and reviews recent clinical data and patient cases, highlighting the various benefits upadacitinib can offer.

Addressing unmet needs in generalized pustular psoriasis: Real-world insights

As a rare and heterogeneous autoinflammatory skin disease, generalized pustular psoriasis (GPP) currently lacks clear and consistent management guidelines, presenting treatment challenges particularly for patients experiencing recurrent flares. This article highlights global GPP data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 and reports recent case series of Chinese and Italian patients with GPP flares treated with spesolimab, an interleukin (IL)-36 receptor antagonist.

Abrocitinib provides early and sustained efficacy in atopic dermatitis

Abrocitinib provides early relief of itch and skin pain as well as sustained efficacy for >2 years in patients with moderate-to-severe atopic dermatitis (AD), post-hoc analyses of JADE trials have shown. Notably, long-term efficacy was observed irrespective of prior exposure to systemic therapies.

Dual JAK3/TEC inhibition may induce hair regrowth in alopecia areata

Dual JAK3/TEC inhibition may induce hair regrowth in alopecia areata (AA), an autoimmune disorder characterized by nonscarring hair loss.

Contemporary management of CRSwNP with an anti–IL-5 biologic

Reducing glucocorticoid use and organ-damage progression in SLE with early use of a B-lymphocyte stimulator antagonist

A 20-year-old nulligravida female student, who was a nonsmoker and nondrinker with good past health, first presented in March 2024. She complained of significant alopecia and photosensitive rash that was slightly itchy but not painful, primarily affecting her face and hands for 2 months. She was generally well with no fever or joint pain, and no family history of rheumatological disorders.

Corticosteroid elimination with anti–IL-5 antibody in two patients with idiopathic HES

A 45-year-old male presented with generalized urticaria in September 2020. He had no past history of allergies, but had transient autoimmune thyroiditis in 2018, which subsequently resolved.